AstraZeneca
ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer
AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer
AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial
AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms
AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study
AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches
NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment
AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks
AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases
AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval
TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)
Relay Therapeutics Advances Towards Pivotal Trial with Promising Breast Cancer Data, Setting Stage for Competition with AstraZeneca’s Truqap
Relay Therapeutics, RLY-2608, Breast Cancer, PI3Kα Mutations, Pivotal Trial, AstraZeneca, Truqap
QIAGEN and AstraZeneca Enhance Partnership to Develop Companion Diagnostics for Chronic Diseases
QIAGEN, AstraZeneca, companion diagnostics, chronic diseases, precision medicine, QIAstat-Dx, genotyping assay
AstraZeneca Invests $135M in Swedish Biologics Manufacturing Expansion
AstraZeneca, biologics manufacturing, Sweden, expansion, investment
FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery
FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC